Catalent Appoints Two Senior Executives to Support Global Development and Clinical Services Business Growth
Catalent Pharma Solutions has announced two appointments to the management structure of its development and clinical services division, to further support its global customer needs. The move sees the creation of two new senior leadership roles to support drug development and clinical trial growth in the US, Europe and Asia.
Mr Paul Hegwood, currently VP Operations for the clinical supply services offerings will assume the new role of VP Operations for the development and clinical services division for the Americas and Asia-Pacific regions. Mr Stuart Cryer, who is currently VP Operations for the development and analytical solutions offerings, will become the new VP Operations for the development and clinical services division for Europe and the rest of world.
“These appointments are part of our strategic investment and growth strategy across our global network, especially for our fast growing clinical supply services network, which comprises eight GMP facilities and over 50 depots across all continents,” commented Scott Houlton, President and CEO, development and clinical services. “The move provides further regional customer focus, plus greater local regulatory expertise, and will facilitate faster execution to support our clients’ needs wherever they are in the world.”
Paul Hegwood was named Vice President of global operational excellence for Catalent in April 2011, following an extensive career leading multi-national teams in operations, business development and product engineering. He had previously held the position of VP of global operations for Stanadyne Corp. and has held various leadership positions at General Motors and its automotive electronics and technology company, Delphi. He holds an MBA from the University of Michigan and a BME from Kettering University. Mr Hegwood is a trained specialist in lean manufacturing and is a certified Six Sigma Green Belt.
Mr Cryer has a Bachelor of Pharmacy honors degree from Bath University and more than 25 years’ experience in the pharmaceutical industry. He has worked for a broad range of pharmaceutical organisations including Pfizer, Abbott, GSK and Aptuit. He has held roles in formulation and development, technical support and operational management.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance